Invesco Pharmaceuticals ETF PJP

PowerShares Dynamic Pharmaceuticals Portfolio (el Fondo) es un fondo no diversificado. El Fondo busca resultados de inversión que se correspondan generalmente con el precio y el rendimiento del Índice Dynamic Pharmaceuticals Intellidex (el Índice). El Índice evalúa empresas basadas en una variedad de criterios de mérito de inversión, incluido el crecimiento fundamental, la valoración de acciones, la oportunidad de inversión y los factores de riesgo. El Índice está compuesto por acciones de 30 empresas farmacéuticas de Estados Unidos. Estas son empresas que se dedican principalmente a la investigación, desarrollo, fabricación, venta o distribución de productos farmacéuticos y medicamentos de todo tipo. El Fondo normalmente invierte al menos el 90% de sus activos totales en acciones comunes que conforman el Índice. El asesor de inversión del Fondo es Invesco PowerShares Capital Management LLC.

Con 8 acciones de PJP (USD 967,70) habrías recibido USD 9,04 en dividendos en los últimos 12 meses.

• Zacks Investment Research 3 sept

  Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

  The Invesco Pharmaceuticals ETF (PJP) is a passively managed fund tracking the Dynamic Pharmaceutical Intellidex Index with $541.13 million in assets. It offers broad exposure to U.S. pharmaceutical companies with a 0.57% expense ratio and 0.82% dividend yield. The ETF has gained 24.96% year-to-date and 41.74% over the past year but carries higher risk with a beta of 0.45 and 16.02% standard deviation. It holds 32 stocks with top positions in Abbott Laboratories, Amgen, and Abbvie, and carries a Zacks ETF Rank of 3 (Hold).

  

• The Motley Fool 28 ago

  Which Healthcare ETF Offers the Better Growth Outlook: VanEck Biotech or Invesco Pharmaceuticals?

  The article compares two healthcare ETFs: VanEck Biotech ETF (BBH) with a lower 0.35% expense ratio and concentrated biotech focus, versus Invesco Pharmaceuticals ETF (PJP) with higher dividend yield and broader pharma exposure. Despite PJP's superior 5-year performance and lower volatility, the article concludes BBH is the better buy based on recent outperformance, though both funds offer targeted healthcare sector exposure with different risk-return profiles.

  

• The Motley Fool 19 ago

  Invesco Nasdaq Biotech vs. Invesco Pharma: How Do These ETFs Stack Up?

  The Invesco Pharmaceuticals ETF (PJP) offers concentrated exposure to 29 pharma giants with better historical returns and lower volatility, while the Invesco Nasdaq Biotechnology ETF (IBBQ) provides broader diversification across 251 holdings at a lower expense ratio of 0.19% versus 0.57%. Despite IBBQ's cost advantage, PJP is recommended as the better buy due to its significantly larger asset base ($512.6M vs $81M), which addresses liquidity concerns.

  

• The Motley Fool 22 jul

  As Healthcare Rallies Is the Vanguard Health Care ETF of the Invesco Pharmaceuticals ETF the Better Fund for 2026?

  The article compares two healthcare-focused ETFs: Vanguard Health Care ETF (VHT) and Invesco Pharmaceuticals ETF (PJP). VHT offers broader sector exposure with 411 holdings, a lower expense ratio of 0.09%, and higher dividend yield of 1.60%. PJP focuses narrowly on 29 pharmaceutical stocks with a 0.57% expense ratio and 0.90% yield. Despite VHT's cost advantages, PJP has significantly outperformed over 3 and 5-year periods (17.3% and 9.1% returns respectively), leading the author to recommend PJP as the better buy for 2026.

  

• The Motley Fool 20 jul

  Will the Invesco Pharma ETF or iShares Global Healthcare Fund Be the Better Health Care Fund in 2026?

  The article compares two healthcare ETFs: Invesco Pharmaceuticals ETF (PJP), which focuses on concentrated U.S. pharma exposure with 29 holdings, and iShares Global Healthcare ETF (IXJ), which offers diversified global healthcare with 110 holdings. PJP delivered superior 1-year returns of 44.90% versus IXJ's 18.20%, though IXJ has a lower expense ratio (0.40% vs 0.57%) and higher dividend yield (1.50% vs 0.90%). The article recommends PJP for investors seeking healthcare exposure due to its stronger performance across most timeframes.